

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER ENDED 31 DECEMBER 2022

(The figures have not been audited)

| | INDIVIDUAL QUARTER | | CUMULATIVE QUARTER | |
|---|---|---|---|--|
| | Current Year Quarter ended 31 Dec 2022 (Unaudited) RM'000 | Preceding Year Corresponding Quarter 31 Dec 2021 (Unaudited) RM'000 | Current Year To-Date 31 Dec 2022 (Unaudited) RM'000 | Preceding Year Corresponding Period 31 Dec 2021 (Audited) RM'000 |
| Revenue | 14,508 | 258,362 | 33,596 | 304,612 |
| Cost of sale | (42,809) | (206,486) | (58,116) | (242,506) |
| Gross profit | (28,301) | 51,876 | (24,520) | 62,106 |
| Other Operating Income | 1,341 | 430 | 6,484 | 1,348 |
| Administrative and distribution expenses | (3,501) | (7,845) | (17,930) | (10,964) |
| Other Operating Expenses | (942) | (2,426) | (2,344) | (7,385) |
| Share of net loss from an associate | - | (80) | (26) | (260) |
| (Loss)/profit before tax | (31,403) | 41,955 | (38,336) | 44,845 |
| Income tax expense | B5 (48) | (11,925) | (619) | (12,206) |
| (Loss)/profit after tax | (31,451) | 30,030 | (38,955) | 32,639 |
| Attributable to : | | | | |
| Equity holders of the parent | (31,845) | 30,133 | (39,392) | 32,046 |
| Non-controlling Interest | 394 | (103) | 437 | 593 |
| | (31,451) | 30,030 | (38,955) | 32,639 |
| Earnings per share attributable to equity holders of parent : | | | | |
| Basic (sen) | B13 (7.625) | 6.827 | (9.432) | 7.677 |
| Diluted (sen) | B13 (7.655) | 6.789 | (9.469) | 7.647 |
| EBITDA ⁽¹⁾ | (1,372) | 29,978 | (7,301) | 46,650 |

Note:-

⁽¹⁾ Profit before interest income, finance cost, tax, depreciation, amortisation and allowances.

(The unaudited Condensed Consolidated Income Statements should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2022
(The figures have not been audited)

| | Unaudited 31 Dec 2022 RM'000 | Audited 31 Dec 2021 RM'000 |
|--|---|---|
| ASSETS | | |
| Non-current assets | | |
| Property, plant and equipment | 28,571 | 28,687 |
| Right-of-use assets | 4,114 | 4,022 |
| Goodwill | 8 | 8 |
| Other receivables | 96 | - |
| | <u>32,789</u> | <u>32,717</u> |
| Current Assets | | |
| Inventories | 3,868 | 30,845 |
| Trade receivables | 9,899 | 32,023 |
| Other receivables | 1,848 | 1,695 |
| Contract Assets | 21,825 | 13,552 |
| Amount due from an associate | - | 1,816 |
| Tax recoverable | 3,908 | 388 |
| Other short term investments | 1,480 | 308 |
| Deposit, cash and bank balances | 13,062 | 53,651 |
| | <u>55,890</u> | <u>134,278</u> |
| TOTAL ASSETS | <u>88,679</u> | <u>166,995</u> |
| EQUITY AND LIABILITIES | | |
| Equity attributable to equity holders of the parent | | |
| Share capital | 80,749 | 80,551 |
| Treasury shares | (280) | (280) |
| Reserves | (8,841) | 37,622 |
| | <u>71,628</u> | <u>117,893</u> |
| Non-controlling interest | 2,409 | 1,972 |
| Total equity | <u>74,037</u> | <u>119,865</u> |
| Non-Current Liabilities | | |
| Term Loan | B7 4,695 | 5,310 |
| Lease liabilities | B7 1,421 | 1,415 |
| Deferred taxation | 33 | - |
| | <u>6,149</u> | <u>6,725</u> |
| Current Liabilities | | |
| Trade payables | 3,359 | 26,215 |
| Other payable & accruals | 1,233 | 4,112 |
| Amount due to director | - | 103 |
| Contract Liabilities | 2,838 | 3,825 |
| Term Loan | B7 501 | 428 |
| Lease liabilities | B7 562 | 510 |
| Taxation | - | 5,212 |
| | <u>8,493</u> | <u>40,405</u> |
| Total liabilities | <u>14,642</u> | <u>47,130</u> |
| TOTAL EQUITY AND LIABILITIES | <u>88,679</u> | <u>166,995</u> |
| Number of ordinary shares in issue ('000) | 441,619 | 441,361 |
| Net assets value per share (RM) | <u>0.1622</u> | <u>0.2671</u> |

(The unaudited Condensed Consolidated Balance Sheet should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED 31 DECEMBER 2022
(The figures have not been audited)

| | 12 months Ended 31 Dec 2022 (Unaudited) RM'000 | 12 months Ended 31 Dec 2021 (Audited) RM'000 |
|--|---|---|
| CASHFLOWS FROM OPERATING ACTIVITIES | | |
| (Loss)/Profit before taxation | (38,336) | 44,845 |
| Adjustment for : | | |
| Depreciation of property, plant and equipment | 737 | 729 |
| Depreciation of right-of-use assets | 616 | 596 |
| Amortisation of intangible assets | - | 5 |
| Gain on disposal of short term investment | - | 20 |
| Dividend income from short term investments | - | (455) |
| Interest income | (190) | (87) |
| Bad debts written off | 187 | 2 |
| Net (gain)/loss on changes in fair value of short term investments | (5) | 1,102 |
| Gain on disposal of property, plant & equipment | (5) | - |
| Interest expense - others | 192 | 215 |
| Net increase in impairment losses on trade receivables and contract assets | 343 | 1,091 |
| Net increase in impairment loss for investment in associate | - | 694 |
| Net increase in impairment losses on other receivables | - | 10 |
| Increase/(decrease) in impairment for amount due from associate | - | (135) |
| Reversal of impairment loss on trade receivables and contract assets | (1,076) | - |
| Intangible assets written off | - | 131 |
| Rent concessions related to Covid-19 | - | (4) |
| Allowance for slow moving inventories | 30,215 | - |
| (Gain)/loss on termination of lease contracts | - | (5) |
| Property, plant and equipment written off | 14 | 45 |
| Share options expenses | 1,800 | - |
| Share of loss/(gain) in an associate | (490) | 260 |
| Unrealised (gain)/loss on foreign exchange | (128) | 4 |
| Operating (loss)/profit before working capital changes | (6,126) | 49,063 |
| Working capital changes : | | |
| (Increase)/ Decrease in inventories | (3,238) | (29,030) |
| (Increase)/ Decrease in contract assets | (8,274) | (9,718) |
| (Increase)/ Decrease in trade and other receivables | 24,237 | (29,582) |
| (Increase)/ Decrease in amount due from associate | - | 6,057 |
| Increase/ (Decrease) in contract liabilities | (987) | 3,243 |
| Increase/ (Decrease) in trade and other payables | (25,245) | 27,681 |
| Increase/ (Decrease) in amount due to director | (103) | 103 |
| Cash (used in)/ generated from operating activities | (19,736) | 17,817 |
| Interest paid | (192) | (215) |
| Tax refunded | 12 | - |
| Tax paid | (9,330) | (7,097) |
| Net cash (used in)/generated from operating activities | (29,246) | 10,505 |
| CASH FLOWS FROM INVESTING ACTIVITIES | | |
| Net (placements)/withdrawal of short term investments | 278 | 30,365 |
| Interest received | 190 | 87 |
| Proceeds from disposal of property, plant and equipment | 173 | 1 |
| Purchase of right of use assets | (738) | - |
| Purchase of property, plant and equipment (include PPE WIP) | (773) | (18,390) |
| Net (placement)/withdrawal of deposits under lien | (3,159) | 1,091 |
| Net cash (used in)/generated from investing activities | (4,029) | 13,154 |
| CASHFLOWS FROM FINANCING ACTIVITIES | | |
| Proceeds from issuance of shares pursuant to exercise of share options | 121 | 218 |
| Proceeds from issuance of shares pursuant to exercise of warrants | - | 13,692 |
| Net repayment of term loan | (541) | (617) |
| Net addition/(repayments) of principal portion of lease liabilities | 58 | (541) |
| Payment of dividends | (8,794) | - |
| Purchase of treasury share | - | (200) |
| Net cash (used in)/generated from financing activities | (9,156) | 12,552 |

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED 31 DECEMBER 2022 (CONT'D)
 (The figures have not been audited)

| | 12 months Ended 31 Dec 2022 (Unaudited) RM'000 | 12 months Ended 31 Dec 2021 (Audited) RM'000 |
|---|---|---|
| Net (decrease)/ increase in cash and cash equivalents | (42,431) | 36,211 |
| Currency translation difference | 128 | (109) |
| Cash and cash equivalents at beginning period | <u>47,011</u> | <u>10,909</u> |
| Cash and cash equivalents at end of period | <u><u>4,708</u></u> | <u><u>47,011</u></u> |
| | - | |

Cash and cash equivalents as at 31 Dec 2022 and 31 Dec 2021 comprise the following :

| | 2022 RM'000 | 2021 RM'000 |
|---|------------------------|------------------------|
| Deposit, cash and bank balances | 13,062 | 53,651 |
| Less: Fixed deposits with licensed banks (pledged with bank for banking facilities) | <u>(8,354)</u> | <u>(6,640)</u> |
| Cash and cash equivalents | <u><u>4,708</u></u> | <u><u>47,011</u></u> |

(The unaudited Condensed Consolidated Cashflow Statements should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER ENDED 31 DECEMBER 2022
(The figures have not been audited)

| | Non-distributable | | | Distributable | | | | |
|--|-------------------------|--------------------------|---------------------------|--|-----------------|--------------------------------------|--|-----------------|
| | Share Capital RM'000 | Option Reserve RM'000 | Treasury Shares RM'000 | Retained Earnings/ (Accumulated Losses) RM'000 | Total RM'000 | Share Application Money RM'000 | Non-controlling Interests RM'000 | Total RM'000 |
| As at 1 January 2021 (audited) | 65,863 | 243 | (79) | 5,451 | 71,478 | 660 | 1,379 | 73,517 |
| Issuance of ordinary shares pursuant to:- | | | | | | | | |
| - Exercise of Share Options | 255 | - | - | - | 255 | (38) | - | 217 |
| - Exercise of Warrants | 14,315 | - | - | - | 14,315 | (622) | - | 13,693 |
| - Private placements | - | - | - | - | - | - | - | - |
| Share Options Reserve | 118 | (118) | - | - | - | - | - | - |
| Share repurchased | | | (201) | - | (201) | - | - | (201) |
| Profit for the financial year and total comprehensive profit for the financial year | | | | 32,046 | 32,046 | - | 593 | 32,639 |
| At 31 Dec 2021 (audited) | 80,551 | 125 | (280) | 37,497 | 117,893 | - | 1,972 | 119,865 |
| As at 1 January 2022 | 80,551 | 125 | (280) | 37,497 | 117,893 | - | 1,972 | 119,865 |
| Issuance of ordinary shares pursuant to:- | | | | | | | | |
| - Exercise of Share Options | 198 | (77) | - | - | 121 | - | - | 121 |
| Share Options Granted | - | 1,800 | - | - | 1,800 | - | - | 1,800 |
| Loss for the financial year and total comprehensive loss for the financial year | - | - | - | (39,392) | (39,392) | - | 437 | (38,955) |
| Dividend paid | - | - | - | (8,794) | (8,794) | - | - | (8,794) |
| At 31 Dec 2022 (unaudited) | 80,749 | 1,848 | (280) | (10,689) | 71,628 | - | 2,409 | 74,037 |

1 Effective from 31st January 2017, the new Companies Act 2016 ("the Act") abolished the concept of authorised share capital and par value of share capital. Consequently, the credit balance of the share premium becomes part of the Company's share capital pursuant to the transitional provision set out in Section 618(2) of the Act. Notwithstanding this provision, the Company may within 24 months from the commencement of the Act, use this amount for purpose set out in Section 618 (3) of the Act. There is no impact on the number of ordinary shares in issue or the relative entitlement of any members as a result of this transition.

(The unaudited Condensed Consolidated Changes In Equity should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER ENDED 31 DECEMBER 2022

A. EXPLANATORY NOTES PURSUANT TO MFRS 134 INTERIM FINANCIAL REPORTING

A1. Basis of preparation

The interim financial report of the Company and its subsidiaries ("Group") is unaudited and is prepared in accordance with MFRS 134 "Interim Financial Reporting" and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") for the ACE Market and should be read in conjunction with the audited consolidated financial statements of the Group for the financial year ended 31 December 2021.

A2. Changes in accounting policies

The accounting policies adopted by the Group in the interim financial report are consistent with those adopted for the audited financial statements of the Group for the financial year ended 31 December 2021 except for the adoption of the following new MFRSs and Amendments to MFRSs that are effective for financial statements effective from 1 January 2022, as disclosed below:

Annual Improvements to MFRS Standards 2018 - 2020
Amendments to MFRS 3 Reference to the Conceptual Framework
Amendments to MFRS 116 Property, Plant and Equipment - Proceeds before Intended Use
Amendments to MFRS 137 Onerous Contracts - Cost of Fulfilling a Contract

The adoption of the above did not have any significant impact on the financial statements of the Group.

A3. Auditors' report on preceding annual financial statements

The auditors' report on the financial statements for the financial year ended 31 December 2021 was not subject to any qualification.

A4. Seasonality or cyclicity factors

The Group's operations were not affected by seasonal or cyclical changes.

A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no unusual items or events affecting assets, liabilities, equity, net income or cash flows of the Group during the quarter under review.

A6. Material changes in estimates

There were no material changes in estimates that have a material effect in the current quarter results.

A7. Debts and equity securities

There were no other issuance, cancellation, resale, repurchase and repayment of debt and equity securities.

A8. Dividends Paid

There was no dividend paid during the quarter under review.

A. EXPLANATORY NOTES PURSUANT TO MFRS 134 INTERIM FINANCIAL REPORTING (CONTD.)

A9. Segmental information

During the financial period, the Group revenue was contributed mainly from the following business segments:

- i) Engineering Equipment Design and development of equipment and software for engineering education, research and technical and vocational training ("TVET") in chemical, mechanical, electrical, civil and control engineering under SOLTEQ brand.
- ii) Industrial Fabrication and Assembly Metal fabrication and assembly works.
- iii) Industrial Automation Provision of industrial automation solutions, currently specialising in water works such as remote monitoring system for dams, tidal control system for irrigation and automation system for flood mitigation under SOLWEB brand.
- iv) Solar Business Promoting all types of businesses relating to green and renewal energy.
- v) Biotechnology & Biopharmaceutical Undertakes all types and kinds of biotechnology business. Fill and finish, marketing and distribution of any type of Biological drugs.
- vi) Industrial Lubricants Production and distribution of industrial lubricants under SOLMAX brand and OEM brand.

Segmental financial information for 12 months period ended 31 Dec 2022 and 31 Dec 2021 are as follows:

| | 2022 | | | | | | | | |
|---|-----------------------|-------------------------------------|-----------------------|-----------------------|---------------------------|----------------|---------|-------------|-----------------|
| | Engineering Equipment | Industrial and Assembly Fabrication | Industrial Automation | Industrial Lubricants | Biotechnology & Biopharma | Solar Business | Others | Elimination | Total |
| | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 |
| Segment revenue | | | | | | | | | |
| External | 5,468 | 1,207 | 16,824 | 1,391 | 709 | 7,988 | 8 | - | 33,595 |
| Inter-segment | 5 | 1,235 | 634 | 2 | 110 | - | - | (1,986) | - |
| Total revenue | 5,473 | 2,442 | 17,458 | 1,393 | 819 | 7,988 | 8 | (1,986) | 33,595 |
| Results | | | | | | | | | |
| Segment results | 76 | 172 | 1,266 | (117) | (38,712) | 779 | (1,278) | (304) | (38,118) |
| Share of loss in an associate | | | | | | | | | (26) |
| Interest expense | | | | | | | | | (192) |
| Loss before taxation ("LBT") | | | | | | | | | (38,336) |
| Income tax expense | | | | | | | | | (619) |
| Loss after taxation ("LAT") | | | | | | | | | (38,955) |
| Non-controlling Interest | | | | | | | | | (437) |
| Loss attributable to equity holders of the company | | | | | | | | | <u>(39,392)</u> |

| | 2021 | | | | | | | | |
|---|-----------------------|-------------------------------------|-----------------------|-----------------------|---------------------------|----------------|--------|-------------|---------------|
| | Engineering Equipment | Industrial and Assembly Fabrication | Industrial Automation | Industrial Lubricants | Biotechnology & Biopharma | Solar Business | Others | Elimination | Total |
| | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 |
| Segment revenue | | | | | | | | | |
| External | 6,298 | 1,143 | 4,734 | 1,220 | 275,426 | 15,789 | 2 | - | 304,612 |
| Inter-segment | 952 | 1,305 | 1,348 | 0 | 158 | - | 16,254 | (20,017) | - |
| Total revenue | 7,250 | 2,448 | 6,082 | 1,220 | 275,584 | 15,789 | 16,256 | (20,017) | 304,612 |
| Results | | | | | | | | | |
| Segment results | (147) | (99) | 659 | (142) | 44,720 | 2,550 | 9,759 | (11,980) | 45,320 |
| Share of loss in an associate | | | | | | | | | (259) |
| Interest expense | | | | | | | | | (215) |
| Profit before taxation ("PBT") | | | | | | | | | 44,846 |
| Income tax expense | | | | | | | | | (12,207) |
| Profit after taxation ("PAT") | | | | | | | | | 32,639 |
| Non-controlling Interest | | | | | | | | | (593) |
| Profit attributable to equity holders of the company | | | | | | | | | <u>32,046</u> |

A10. Valuation of property, plant and equipment

The Group did not revalue any of its property, plant and equipment during the quarter under review.

A11. Material events subsequent to the end of the quarter

There were no material events occurring subsequent to the end of the reporting period to the date of announcement.

A12. Changes in the composition of the Group

There were no changes in the composition of the Group for the quarter under review.

A13. Contingent liabilities

There were no material contingent liabilities as at the date of this announcement.

A14. Capital commitment

There were no material capital commitment as at the date of this announcement.

A15. Significant Related Party Transaction

There was no significant related party transaction as at the date of this announcement.

**B. ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD
LISTING REQUIREMENTS FOR THE ACE MARKET**

B1. Review of Performance

Comparison with corresponding quarter in previous financial year

The Group recorded a revenue of RM14.51 million during the quarter, a decrease of RM243.85 million as compared to the revenue of RM258.36 million in the corresponding quarter in previous financial year. The significant decrease in revenue was mainly attributable to lower sales in the biopharma business segment.

For the quarter ended 31 Dec 2022, the Group recorded a loss after tax ("LAT") of RM31.45 million. In the preceding year quarter ended 31 Dec 2021, the Group reported profit after tax ("PAT") of RM30.03 million. The loss reported in this quarter was mainly attributed to impairment of the COVID-19 vaccine slow moving stocks of RM30.19 million. The decrease in sales and high operating expenses in the biopharma business segment have also contributed to the Group's overall loss.

B2. Comparison with Preceding Quarter's Results

The Group's revenue for the quarter under review was RM14.51 million, an increase of RM8.49 million, as compared to the revenue of RM6.02 million registered in the preceding quarter.

The Group reported a loss after tax of RM31.45 million during the quarter, significantly increase in loss as compared to the loss of RM3.05 million in the preceding quarter. The loss reported in this quarter was mainly attributed to impairment on the COVID-19 vaccine slow moving stocks of RM30.19 million, decrease in sales and high operating expenses mainly incurred by the biopharma business segment.

B3. Prospects for next financial year 2023

Solution Biologics Sdn Bhd and CanSino Biologics Inc.'s ("CanSino") had completed the world's first clinical trial to test on the efficacy and safety of an inhaled vaccine from CanSino Biologics Inc.'s ("CanSino") Recombinant Adenovirus Type 5 Vector vaccine, Convidecia Air™ as a second booster against various COVID-19 variants. The clinical trial report will be out in the first half of 2023.

The Group is applying product registration for Convidecia Air™ with National Pharmaceutical Regulatory Agency by first half of 2023. The inhaled vaccine has been rolled out in China since October 2022.

CanSino has about 13 types of vaccines in their product development pipelines, SOLBIO collaborates closely with CanSino in commercialising the products in Malaysia and also ASEAN.

On 25 May 2022, SOLBIO, National Institute of Biotechnology Malaysia ("NIBM") and CanSino had signed a MOU on the collaboration of human vaccine R&D. As at todate, there is no material development on the MOU as the parties are still in the stage of finalizing a definitive agreement.

The Group is diversifying its business operations by venturing into plant construction works through its subsidiary Solution A & C Technology Sdn. Bhd. ("SACT"), where the new venture is performing well. The Group is expecting its other business segments to recover and contribute to its financial performance. Additionally, the Group is also exploring the mergers and acquisitions as a means of expanding its solar business. The Group is taking a proactive approach to expanding and diversifying its business operations, which could lead to greater success and stability in the long run.

B4. Profit guarantee

The Group has not issued any profit forecast nor guarantee in respect of any corporate proposal.

B5. Taxation

| | Quarter ended | | Year-to-date | |
|-------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| | 31 Dec 2022 RM'000 | 31 Dec 2021 RM'000 | 31 Dec 2022 RM'000 | 31 Dec 2021 RM'000 |
| Current taxation | | | | |
| -Provision for taxation | (48) | (11,925) | (619) | (12,206) |
| Deferred taxation | - | - | - | - |
| | (48) | (11,925) | (619) | (12,206) |

B6. Profit on sale of unquoted investments and/or properties

There were no disposal of unquoted investment and/or properties for the quarter under review.

B7. Group borrowings and debt securities

Details of the Group's borrowings as at 31 Dec 2022 are as follows :

| | Current RM'000 | Non-current RM'000 | Total RM'000 |
|---|-------------------|-----------------------|-----------------|
| Secured : | | | |
| Hire purchase (included in lease liabilities) | 146 | 647 | 793 |
| Term loan | 501 | 4,695 | 5,196 |
| Total | 647 | 5,342 | 5,989 |

B8. Status of Corporate Proposals

A) Update on Employees' Share Option Scheme (ESOS) as at 31 Dec 2022

The Company had obtained its shareholders approval for the establishment of the ESOS of up to 30% of the total issued and paid-up share capital for the eligible employees and directors and its subsidiaries at the EGM dated 16 January 2014.

Below are the details of the shares that had been granted and exercised under the ESOS as at 31 Dec 2022:

| ESOS Option Grant Date | Expiry Date | Exercise Price | No. of Share | | No. of Share Lapsed | Status |
|------------------------|-------------|----------------|----------------------|----------------------|---------------------|-----------|
| | | | No. of Share Granted | Exercised and Listed | | |
| 22 July 2014 | 29 Jan 2019 | RM0.135 | 11,134,000 | 11,103,000 | 31,000 | Completed |
| 8 January 2015 | 29 Jan 2019 | RM0.185 | 6,000,000 | 6,000,000 | - | Completed |
| 28 September 2016 | 29 Jan 2024 | RM0.220 | 6,000,000 | 4,473,000 | 422,000 | Ongoing |
| 8 August 2020 | 29 Jan 2024 | RM0.175 | 2,605,000 | 2,150,000 | | Ongoing |
| 9 February 2022 | 29 Jan 2024 | RM0.470 | 6,000,000 | 257,000 | | Ongoing |

On 22 January 2019, the Company had announced to extend the existing ESOS of the Company which commenced on 30 January 2014 and expired on 29 January 2019 for another five (5) years until 29 January 2024 in accordance with the terms of the ESOS Bylaws.

B) Proposed Renewal of Authority for the Company to Purchase Its Own Shares

The Renewal of Authority for Share Buy Back had been approved by shareholders at the Seventeenth Annual General Meeting of the Company. As at todate, the total number of treasury shares is 1,932,700.

B9. Realised/ Unrealised Profits

| | As at 31 Dec 2022 RM'000 |
|--|--------------------------------|
| Total accumulated losses of the Company and its subsidiaries | |
| - realised | (6,334) |
| - unrealised | 133 |
| | (6,201) |
| Less: Consolidated adjustments | (4,488) |
| Accumulated losses as per financial statement | (10,689) |

**B. ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD
LISTING REQUIREMENTS FOR THE ACE MARKET (CONTD.)**

B10. Profit Before Tax

| | Quarter ended 31 Dec 2022 RM'000 | Quarter ended 31 Dec 2021 RM'000 |
|--|--|--|
| Profit before tax is derived after charging: | | |
| Depreciation of property, plant & equipment | 180 | 124 |
| Depreciation of right-of-use assets | 156 | 161 |
| Amortisation of intangible asset | - | 1 |
| Impairment on investment in associated company | - | 694 |
| Impairment on trade receivables and contract asset | 343 | 1,337 |
| Allowance for slow moving inventories | 30,215 | - |
| Loss on disposal of property, plant & equipment | 19 | - |
| Loss on disposal of investment | 165 | - |
| Interest expense | 63 | 60 |
| Loss on foreign exchange: | | |
| -Realised | 46 | 285 |
| Bad debts written off | - | 2 |
| Property, plant & equipment written off | - | 44 |
| and crediting: | | |
| Interest income | (48) | (31) |
| Dividend income from other investment | - | (1) |
| Gain on changes in fair value of short term investment | - | (1) |
| Reversal of impairment on trade receivables and contract asset | (615) | (366) |
| Gain on foreign exchange: | | |
| -Unrealised | (123) | (543) |

B11. Off balance sheet financial instruments

There were no financial instruments with off-balance sheet risk as at the date of this announcement applicable to the Group.

B12. Dividends

The Board of Directors did not recommend other payment of dividend in respect of the quarter under review.

B13. Earnings per share

| | Current Quarter ended 31 Dec 2022 | Comparative Quarter ended 31 Dec 2021 | Current year to date ended 31 Dec 2022 | Preceding year to date ended 31 Dec 2021 |
|---|--|--|---|---|
| Net profit/(loss) for the period attributable to equity holders (RM'000) | (31,845) | 30,133 | (39,392) | 32,045 |
| Basic | | | | |
| Weighted average number of ordinary shares in issue ('000) | 417,621 | 441,361 | 417,621 | 417,407 |
| Basic EPS (sen) | (7.625) | 6.827 | (9.432) | 7.677 |
| Diluted | | | | |
| Weighted average number of ordinary shares in issue ('000) | 417,621 | 441,361 | 417,621 | 417,407 |
| Effect of dilution: share options and convertible warrants ('000) | (1,626) | 2,472 | (1,626) | 1,642 |
| Adjusted weighted average number of ordinary shares in issue and issuable ('000) | 415,995 | 443,833 | 415,995 | 419,049 |
| Diluted EPS (sen) | (7.655) | 6.789 | (9.469) | 7.647 |

**BY ORDER OF THE BOARD
SOLUTION GROUP BERHAD**